Selective Covalent Targeting of Anti-Apoptotic BFL-1 by Cysteine-Reactive Stapled Peptide Inhibitors
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Summary Anti-apoptotic BCL-2 family proteins block cell death by trapping the critical α-helical BH3 domains of pro-apoptotic members in a surface groove. Cancer cells hijack this survival mechanism by overexpressing a spectrum of anti-apoptotic members, mounting formidable apoptotic blockades that resist chemotherapeutic treatment. Drugging the BH3-binding pockets of anti-apoptotic proteins has become a highest priority goal, fueled by the clinical success of ABT-199, a selective BCL-2 inhibitor, in reactivating apoptosis in BCL-2 dependent cancers. BFL-1 is a BCL-2 homologue implicated in melanoma, lymphoma, and other cancers, and remains undrugged. A natural juxtaposition of two unique cysteines at the binding interface of the NOXA BH3 helix and BFL-1 pocket informed the development of stapled BH3 peptides bearing acrylamide warheads to irreversibly inhibit BFL-1 by covalent targeting. Given the frequent proximity of native cysteines to regulatory binding surfaces, covalent stapled peptide inhibitors provide a new therapeutic strategy for targeting pathologic protein interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70604-1 · Cited by 1,978
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Structure of Bcl-x L -Bak Peptide Complex: Recognition Between Regulators of Apoptosis
Sattler, M., Liang, H., Nettesheim, D., Meadows, R. P., Harlan, J. E., Eberstadt, M., Yoon, H. S., Shuker, S. B., Chang, B. S., Minn, A. J., et al. (1997) · Science · doi:10.1126/science.275.5302.983 · Cited by 1,476 · cited 1×
“The canonical mechanism for apoptotic suppression involves sequestration of the BH3 killer domain helices of pro-apoptotic members in a binding pocket composed of the BH1, BH2, and BH3 domains of the anti-apoptotic BCL-2, BCL-XL, BCL-w, MCL-1, BFL-1, and BCL-B proteins(Sattler et al., 1997).”
BackgroundBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447 · cited 1×
“Afatinib is an irreversible covalent inhibitor that selectively targets the receptor tyrosine kinases EGFR and HER2, and has been approved by the FDA for treatment of metastatic, EGFR T790Mmutant non-small cell lung cancer(Li et al., 2008; Miller et al., 2012; Solca et al., 2012; Wu et al., 2014).”
BackgroundActivation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix
Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., & Korsmeyer, S. J. (2004) · Science · doi:10.1126/science.1099191 · Cited by 1,349
Self-citationProgrammed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031 · cited 2×
“, 2013), was refined for selective BCL-2 inhibition at least in part to avoid the adverse effect of BCLXL inhibition on platelet survival(Mason et al., 2007; Souers et al., 2013).”
BackgroundMiller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70087-6 · Cited by 961 · cited 2×
“The development of covalent inhibitors for intracellular protein targets has seen a recent resurgence, owing to the breakthrough success of such agents as ibrutinib and afitinib(Burger et al., 2015; Miller et al., 2012; Treon et al., 2015; Wu et al., 2014).”
BackgroundThe Mediator complex: a central integrator of transcription
Allen, B. L., & Taatjes, D. J. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3951 · Cited by 922
Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197756 · Cited by 865 · cited 1×
“Afatinib is an irreversible covalent inhibitor that selectively targets the receptor tyrosine kinases EGFR and HER2, and has been approved by the FDA for treatment of metastatic, EGFR T790Mmutant non-small cell lung cancer(Li et al., 2008; Miller et al., 2012; Solca et al., 2012; Wu et al., 2014).”
BackgroundBAX activation is initiated at a novel interaction site
Gavathiotis, E., Suzuki, M., Davis, M. L., Pitter, K., Bird, G. H., Katz, S. G., Tu, H.-C., Kim, H., Cheng, E. H.-Y., Tjandra, N., et al. (2008) · Nature · doi:10.1038/nature07396 · Cited by 700 · cited 2×
“Our earliest classes of all-hydrocarbon stapled peptides were modeled after the BH3 domains of BID(Walensky et al., 2004; Walensky et al., 2006) and BIM(Gavathiotis et al., 2010; Gavathiotis et al., 2008; LaBelle et al., 2012), two pro-apoptotic BCL-2 family members of Cell Chem Biol.”
BackgroundSelf-citationLeverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.561 · Cited by 440 · cited 3×
“To that end, the race is on for advancing the first, selective, small-molecule inhibitor of MCL-1 to the clinic(Leverson et al., 2015; Pelz et al., 2016), given the prominence of this protein as one of the top ten most expressed pathologic proteins across all subtypes of human cancers(Beroukhim et…”
BackgroundThe Fas–FADD death domain complex structure unravels signalling by receptor clustering
Scott, F. L., Stec, B., Pop, C., Dobaczewska, M. K., Lee, J. J., Monosov, E., Robinson, H., Salvesen, G. S., Schwarzenbacher, R., & Riedl, S. J. (2009) · Nature · doi:10.1038/nature07606 · Cited by 384 · cited 2×
“…to the regulatory “helixin-groove” binding surfaces of a host of therapeutic targets (Figure S6)(Allen and Taatjes, 2015; Kise et al., 2004; Kitagawa et al., 2006; Margarit et al., 2003; Scott et al., 2009), we envision that our covalent stapled peptide inhibitor approach could be broadly applied.”
BackgroundBH3-Triggered Structural Reorganization Drives the Activation of Proapoptotic BAX
Gavathiotis, E., Reyna, D. E., Davis, M. L., Bird, G. H., & Walensky, L. D. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.10.019 · Cited by 310 · cited 2×
“Our earliest classes of all-hydrocarbon stapled peptides were modeled after the BH3 domains of BID(Walensky et al., 2004; Walensky et al., 2006) and BIM(Gavathiotis et al., 2010; Gavathiotis et al., 2008; LaBelle et al., 2012), two pro-apoptotic BCL-2 family members of Cell Chem Biol.”
BackgroundSelf-citation
Cited by
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Vogler, M., Braun, Y., Smith, V. M., Westhoff, M.-A., Pereira, R. S., Pieper, N. M., Anders, M., Callens, M., Vervliet, T., Abbas, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02176-0 · Cited by 462
Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening
Resnick, E., Bradley, A., Gan, J., Douangamath, A., Krojer, T., Sethi, R., Geurink, P. P., Aimon, A., Amitai, G., Bellini, D., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b02822 · Cited by 335
Stapled Helical Peptides Bearing Different Anchoring Residues
Li, X., Chen, S., Zhang, W.-D., & Hu, H.-G. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00532 · Cited by 289
Covalent inhibitors: an opportunity for rational target selectivity
Lagoutte, R., Patouret, R., & Winssinger, N. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.05.008 · Cited by 138
Metadata
- Authors
- Huhn, A. J., Guerra, R. M., Harvey, E. P., Bird, G. H., & Walensky, L. D.
- Venue
- Cell Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 23
- Issue
- 9
- Pages
- 1123-1134
- ISSN
- 2451-9448 (ISSN-L)
- 2451-9456
- OpenAlex
- W2518692338
- Cited by
- 78
- References
- 15
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.